TY - JOUR
T1 - The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer
AU - Rades, Dirk
AU - Warwas, Britta
AU - Cremers, Florian
AU - Gerull, Karsten
AU - Pries, Ralph
AU - Leichtle, Anke
AU - Bruchhage, Karl L.
AU - Hakim, Samer G.
AU - Schild, Steven E.
N1 - Publisher Copyright:
© 2022 International Institute of Anticancer Research. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Background/Aim: Xerostomia is a serious complication following radiotherapy of head-and-neck cancers. A prognostic tool was developed for estimating its risk. Patients and Methods: In our previous study, age, tumor site, bilateral lymph node involvement, definitive radiotherapy, and addition of systemic therapies showed significant associations with grade ≥3 late xerostomia or trends. In additional analyses, mean radiation dose to ipsilateral parotid gland was significant (p=0.011). These six factors were included in the prognostic tool. Scoring points of 0 (lower risk) or 1 (higher risk) were assigned to each factor and added for each patient. Results: Patient scores ranged between 0 and 6; Grade ≥3 xerostomia rates were 0%, 8%, 24%, 26%, 25%, 42%, and 100%, respectively. Three groups were designed (0-1, 2-4, and 5-6 points) with grade ≥3 xerostomia rates of 5%, 25%, and 50%, respectively (p<0.001). Conclusion: This new tool helps estimating the risk of radiation-induced grade ≥3 xerostomia. It can support physicians and other medical staff members during treatment planning.
AB - Background/Aim: Xerostomia is a serious complication following radiotherapy of head-and-neck cancers. A prognostic tool was developed for estimating its risk. Patients and Methods: In our previous study, age, tumor site, bilateral lymph node involvement, definitive radiotherapy, and addition of systemic therapies showed significant associations with grade ≥3 late xerostomia or trends. In additional analyses, mean radiation dose to ipsilateral parotid gland was significant (p=0.011). These six factors were included in the prognostic tool. Scoring points of 0 (lower risk) or 1 (higher risk) were assigned to each factor and added for each patient. Results: Patient scores ranged between 0 and 6; Grade ≥3 xerostomia rates were 0%, 8%, 24%, 26%, 25%, 42%, and 100%, respectively. Three groups were designed (0-1, 2-4, and 5-6 points) with grade ≥3 xerostomia rates of 5%, 25%, and 50%, respectively (p<0.001). Conclusion: This new tool helps estimating the risk of radiation-induced grade ≥3 xerostomia. It can support physicians and other medical staff members during treatment planning.
UR - http://www.scopus.com/inward/record.url?scp=85131156434&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/485cbeeb-728a-3251-943e-50f46a9d823e/
U2 - 10.21873/anticanres.15789
DO - 10.21873/anticanres.15789
M3 - Journal articles
C2 - 35641296
AN - SCOPUS:85131156434
SN - 0250-7005
VL - 42
SP - 3035
EP - 3039
JO - Anticancer Research
JF - Anticancer Research
IS - 6
ER -